Assess whether pediatric studies are necessary or waivable (b8ad38)

Situation

RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT has one working extract — disproportionate reporting signal workbook — after an AdCom briefing document that overstates subgroup findings. RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT has disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings. If that extract cannot support pediatric studies are necessary, the honest Pharma & Life Sciences Pharmacovigilance output is hold.

Decision

RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose Pediatric studies are necessary / Waivable using disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• Disproportionate reporting signal workbook reads as Pediatric studies are necessary once an AdCom briefing document that overstates subgroup findings is lined up to the same Pharma & Life Sciences population.
• Disproportionate reporting signal workbook is closer to Waivable after an AdCom briefing document that overstates subgroup findings; Pediatric studies are necessary would over-claim this Pharmacovigilance extract.
• A dual reading is still live in disproportionate reporting signal workbook for RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT.
• Disproportionate reporting signal workbook is missing the fact RWE evidence-strategy director needs after an AdCom briefing document that overstates subgroup findings; stop this Pharma & Life Sciences close.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• Check whether disproportionate reporting signal workbook supports the labeled claim RWE evidence-strategy director would keep.
• For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against an AdCom briefing document that overstates subgroup findings and write the one fact that would move pediatric studies are necessary for RWE evidence-strategy director.